The European Medicines Agency’s (EMA) drug approval committee has indicated it is likely to reject XBiotech’s metastatic colorectal cancer candidate when it holds a formal vote next month. Shares in ...
With New Infectious Strain Rapidly Spreading, XBiotech Establishes Data Indicating its Candidate True Human™ COVID-19 Therapy may be Effective for Treating New Mutant Strain AUSTIN, Texas, Jan. 21, ...
XBiotech said its data in certain colon cancer patients were “positive,” but this has been ridiculed by some analysts and put its future European approval--which the data were to be used toward--under ...
XBiotech will continue its True Human anti IL-1⍺ antibody discovery program outside of dermatology and use its manufacturing technology to produce clinical supplies of bermekimab for Janssen AUSTIN, ...
Donors with Potent Natural Immunity Against the Virus are Identified as the Starting Point for XBiotech’s Drug Development Program to Treat COVID-19 AUSTIN, Texas, May 01, 2020 (GLOBE NEWSWIRE) -- ...
AUSTIN, Texas, May 17, 2023 (GLOBE NEWSWIRE) -- Xbiotech Inc. (XBIT) (“Xbiotech”) announced today that it commenced a “modified Dutch auction” issuer tender offer to purchase up to $80,000,000 in ...
What: XBiotech fell 33% today, after presenting phase 3 clinical trial results for its colon-cancer drug Xilonix at the 18th European Society of Medical Oncology World Congress on Gastrointestinal ...
After early findings were “not sufficient to meet efficacy,” XBiotech discontinued its phase III study of its novel candidate antibody therapy for colorectal cancer. 1. An Independent Data Monitoring ...
AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc. (XBIT) today announced that it plans to expand it’s campus headquarters with the construction of a new, state-of-the-art research and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results